Ipamorelin is a synthetic peptide used primarily to stimulate the body’s natural production of growth hormone. It works by mimicking ghrelin, a hunger-related hormone that signals the pituitary gland to release growth hormone in pulses. What sets ipamorelin apart from older growth hormone-releasing peptides is its selectivity: it triggers growth hormone release without meaningfully raising cortisol (a stress hormone) or prolactin, even at doses more than 200 times higher than what’s needed for growth hormone stimulation. That clean profile is the main reason it became popular in anti-aging and wellness clinics.
How Ipamorelin Works
Your pituitary gland naturally releases growth hormone in pulses throughout the day, with the largest bursts occurring during deep sleep. Ipamorelin binds to the same receptor that ghrelin uses, essentially telling the pituitary to fire off an additional pulse of growth hormone. The key difference between ipamorelin and earlier peptides like GHRP-6 is that ipamorelin doesn’t trigger a cascade of other hormones. It leaves follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, and prolactin levels unchanged. It also doesn’t spike cortisol, which is a notable advantage since elevated cortisol can break down muscle tissue and promote fat storage.
A 1998 study published in the European Journal of Endocrinology described ipamorelin as “the first selective growth hormone secretagogue,” noting that its specificity for growth hormone release was comparable to the body’s own growth hormone-releasing hormone (GHRH). That selectivity is rare among synthetic peptides in this class and is the foundation of its appeal.
Common Uses in Wellness Settings
Ipamorelin is not FDA-approved for any medical condition. It is, however, widely prescribed through wellness and anti-aging clinics for purposes related to the downstream effects of increased growth hormone. The most common reasons people use it include improving body composition, accelerating recovery from exercise or injury, and counteracting age-related decline in growth hormone output, which begins dropping steadily after age 30.
Growth hormone influences a broad range of processes: it promotes the creation of new muscle cells, increases the rate at which your body breaks down stored fat (lipolysis), supports collagen production, and plays a role in tissue repair. By raising growth hormone levels, ipamorelin is used as a tool to tap into those effects without injecting synthetic growth hormone directly. Some clinics report that patients see a 5 to 10 percent reduction in body fat and roughly a 10 percent increase in lean muscle mass over six months, though individual results vary significantly based on diet, exercise, and baseline hormone levels.
Gut Motility and Postoperative Recovery
Beyond wellness applications, ipamorelin was studied in clinical trials for a very different purpose: helping the gut recover after abdominal surgery. When patients undergo bowel resection (removal of part of the small or large intestine), the digestive system often slows down or temporarily stops, a condition called postoperative ileus. This can delay hospital discharge and increase complications.
Ghrelin receptor agonists like ipamorelin stimulate gastrointestinal motility, the wave-like contractions that move food through the digestive tract. A Phase II clinical trial evaluated whether ipamorelin could reduce the time it takes for normal gut function to return after bowel surgery. While full results from that trial were never publicly posted, the rationale was strong enough to move through multiple phases of development for gastrointestinal dysmotility.
Effects on Bone Health
Animal research has shown that ipamorelin increases bone mineral content. In a study on adult female rats, treatment with ipamorelin led to measurable increases in total bone mineral content in both the tibia and vertebrae. The mechanism was not an increase in bone density per se, but rather an increase in bone dimensions: the bones grew larger in cross-sectional area, with greater cortical (outer shell) mineral content. The actual density of the bone tissue itself remained unchanged, meaning the bones became bigger and stronger without becoming denser per unit of volume.
This distinction matters because it suggests ipamorelin’s bone effects come from stimulating new bone growth rather than packing more mineral into existing bone. These findings have not been replicated in human clinical trials, so the relevance to human bone health remains uncertain.
Pairing With CJC-1295
One of the most common protocols in clinical wellness settings combines ipamorelin with CJC-1295, a modified version of growth hormone-releasing hormone. The two peptides work through different mechanisms that complement each other. CJC-1295 extends the duration of each growth hormone pulse by keeping the “release” signal active longer. Ipamorelin amplifies the strength of each pulse. Used together, the combination produces a more sustained and robust elevation in growth hormone throughout the day and night than either peptide achieves alone.
This pairing has become something of a standard protocol in anti-aging medicine, often prescribed as a single combined injection rather than two separate ones.
Typical Protocols
Ipamorelin is administered by subcutaneous injection, typically in the abdominal area or thigh. The most common dosing range is 200 to 300 micrograms per day, often split into two injections: one in the morning and one before bed. Splitting the dose mimics the body’s natural pattern of pulsatile growth hormone release rather than creating a single large spike.
Beginners often start at 100 to 150 micrograms once daily, usually before bed to coincide with the body’s largest natural growth hormone pulse during deep sleep. More aggressive protocols go up to 400 micrograms per day divided between morning and evening doses. Cycle length typically runs 12 to 16 weeks, with a minimum of 8 weeks needed to see meaningful results. Some individuals use it continuously for up to six months under medical supervision.
Regulatory Status
Ipamorelin has no FDA approval for any indication. It has historically been available through compounding pharmacies, which can prepare custom medications that aren’t commercially manufactured. However, in October 2024, the FDA’s Pharmacy Compounding Advisory Committee reviewed ipamorelin (both the free base and acetate forms) and proposed that neither be included on the list of approved bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. If finalized, this would significantly restrict legal access to ipamorelin through compounding pharmacies in the United States.
For competitive athletes, the question is straightforward. The World Anti-Doping Agency classifies ipamorelin as a prohibited substance under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), specifically as a growth hormone secreting agent. It is banned at all times, both in and out of competition, and is classified as a non-specified substance, meaning there is no reduced sanction for accidental use.